GLP 3 (R)

DESCRIPTION

Retatrutide (GGG Tri-Agonist) is a single-peptide 39-amino-acid triple hormone receptor agonist designed for concurrent activation of GLP-1, GIP, and glucagon receptors.

BENEFITS (RESEARCH FOCUS)

• Triple Hormone Receptor Agonism: Displays potent agonist activity across GLP-1R, GIPR, and GCGR targets.
• Enhanced Energy Expenditure: Glucagon receptor stimulation boosts basal metabolic rate and hepatic lipid oxidation.
• Glycemic & Appetite Control: Synergistic GIP/GLP-1 activation enhances glucose-stimulated insulin release and satiety signaling.

WHAT RESEARCHERS LOOK AT

• cAMP accumulation assays across human GLP-1, GIP, and Glucagon receptors
• Hepatic fat content reduction and beta-oxidation gene expression
• Glucose-dependent insulin secretion and satiety hormone flux

QUICK SPECS

• Form: Lyophilized peptide powder
• Purity: >99% (RP-HPLC)
• Quantity: 1 vial
• Reconstitution: Reconstitute with sterile bacteriostatic water
• Storage: Store at 2-8 deg C, protect from heat and light

Quality Assurance

Each batch is independently verified for purity, identity, and sterility by Peptide Test Canada. A Certificate of Analysis is available for every lot. All compounds are produced under strict quality control conditions and shipped under cold-chain protocols from within Canada.

This compound is available exclusively for in vitro laboratory research and scientific study conducted within Canada. It is not a drug, natural health product, or food product as defined under the Food and Drugs Act (R.S.C., 1985, c. F-27). It is not approved for human consumption, veterinary use, or any diagnostic or therapeutic application. This product has not been evaluated by Health Canada. Researchers are responsible for compliance with all applicable federal, provincial, and local regulations.